Clinical features and insulin regulation in infants with a syndrome of prolonged neonatal hyperinsulinism.
OBJECTIVE
To characterize the clinical features and insulin regulation in infants with hypoglycemia due to prolonged neonatal hyperinsulinism.


METHODS
Data were collected on 26 infants with hypoglycemia due to neonatal hyperinsulinism that later resolved. Acute insulin response (AIR) tests to calcium, leucine, glucose, and tolbutamide were performed in 11 neonates. Results were compared to children with genetic hyperinsulinism due to mutations of the adenosine triphosphate-dependent potassium (K(ATP)) channel and glutamate dehydrogenase (GDH).


RESULTS
Among the 26 neonates, there were significantly more males, small-for-gestational-age infants, and cesarean deliveries. Only 5 of the 26 had no identifiable risk factor. Hyperinsulinism was diagnosed at a median age of 13 days (range, 2 to 180 days) and resolved by a median age of 181 days (range, 18 to 403 days). Diazoxide was effective in 19 of the 21 neonates treated. In the 11 neonates tested, the AIRs to calcium, leucine, glucose, and tolbutamide resembled those in normal controls and differed from genetic hyperinsulinism due to K(ATP) channel and GDH mutations.


CONCLUSIONS
We define a syndrome of prolonged neonatal hyperinsulinism that is responsive to diazoxide, persists for several months, and resolves spontaneously. AIR tests suggest that both the K(ATP) channel and GDH have normal function.
Divisions of Endocrinology and Neonatology, Department of Pediatrics, Children's Hospital of Philadelphia, 34th Street and Civic Center Boulevard, Philadelphia, PA 19104, USA.
Francis M
FM
Hoe
Paul S
PS
Thornton
Laura A
LA
Wanner
Linda
L
Steinkrauss
Rebecca A
RA
Simmons
Charles A
CA
Stanley
D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002118:Calcium / Q000494:pharmacology; D016022:Case-Control Studies; D003981:Diazoxide / Q000627:therapeutic use*; D004750:Enteral Nutrition; D005215:Fasting; D005260:Female; D005947:Glucose / Q000494:pharmacology; D006801:Humans; D006946:Hyperinsulinism / Q000150:complications / Q000175:diagnosis / Q000628:therapy*; D007003:Hypoglycemia / Q000209:etiology / Q000628:therapy*; D007004:Hypoglycemic Agents / Q000494:pharmacology; D007223:Infant; D007231:Infant, Newborn; D007262:Infusions, Intravenous; D007328:Insulin / Q000097:blood / Q000378:metabolism; D000078790:Insulin Secretion; D007930:Leucine / Q000494:pharmacology; D008297:Male; D011446:Prospective Studies; D012307:Risk Factors; D013549:Sweetening Agents / Q000494:pharmacology; D014044:Tolbutamide / Q000494:pharmacology
D000959:Antihypertensive Agents; D007004:Hypoglycemic Agents; D007328:Insulin; D013549:Sweetening Agents; D014044:Tolbutamide; D007930:Leucine; D005947:Glucose; D003981:Diazoxide; D002118:Calcium